Most Read Articles
01 May 2014

New drug applications approved by US FDA as of 15-30 May which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

28 Apr 2017
Silymarin does not appear to be significantly better than placebo in reducing disease activity by 30 percent or more in patients with nonalcoholic steatohepatitis (NASH), according to the results of a trial.
08 May 2017
Transabdominal bowel wall ultrasonography shows utility in monitoring disease activity in patients with active Crohn’s disease (CD), according to a study. The imaging technique is ideal for evaluating early transmural changes in disease activity, in response to medical treatment.

HRT associated with cholelithiasis risk

Audrey Abella
21 Apr 2017

Hormone replacement therapy (HRT), but not oral contraceptives (OC), could lead to the development of gallstones, a recent study has found.

In this meta-analysis, exogenous oestrogen intake was associated with risk of cholelithiasis (pooled risk ratio [RR], 1.59, 95 percent confidence interval [CI], 1.44–1.75). [Medicine (Baltimore) 2017;96:e6556]

However, on subgroup analysis, risk of cholelithiasis was significantly associated with HRT (pooled RR, 1.79, 95 percent CI, 1.61–2.00) but not with OC (pooled RR, 1.19, 95 percent CI, 0.97–1.45).

“[Our study] indicates that OC is not the risk factor for cholelithiasis, which will be beneficial to eliminate the bias for the OC. As for the HRT, our results proved it can significantly increase the incidence of cholelithiasis,” said the researchers.

Results from the researchers’ original study conducted on a postmenopausal Chinese female population further support these findings, which revealed a high risk of cholelithiasis with HRT (RR, 2.01, 95 percent CI, 1.43–2.83 for <2 years and RR, 1.78, 95 percent CI, 1.02–3.60 for ≥2 years) and OC intake (RR, 1.23, 95 percent CI, 0.90–1.68 for <1 year and RR, 1.52, 95 percent CI, 0.64–3.60 for ≥1 year).

Previous studies evaluating the molecular mechanism of oestrogen in the bile duct and gall bladder revealed G protein-coupled receptor 30 and oestrogen receptor α as influential in lipid metabolism, which could increase the likelihood of gallstone formation. [Biochim Biophys Acta 2015;1852:2161-2169; Gastroenterology 2015;148:S295; J Lipid Res 2015;56:1691-700]

Researchers evaluated 19 studies comprising participants aged 14–80 years who were on OC or HRT. Of note is one study that reported oestrogen use in males with prostate cancer, implying that oestrogen could also be a potential risk factor for gallstones in the male population. [J Clin Invest 1989;84:811-816] Further studies are warranted to verify this theory, noted the researchers.

Exogenous oestrogen has been associated with more serious cancer risks (eg, breast, ovarian, endometrial), but its effect on gallstone formation has not been extensively studied. Furthermore, previous studies have shown both positive and negative associations between gallstone formation and HRT and OC intake. [Drug Saf 2013;36:1189-1197; JAMA 2005;293:330-339; Scand J Gastroenterol 2014;49:109-113; Ann Intern Med 2001;135:493-501]

Therefore, it is important to establish a definitive link between cholelithiasis and oestrogen therapy to help clinicians in the management of gallstones, said the researchers, adding that this could raise awareness for overweight women under exogenous oestrogen therapy.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 May 2014

New drug applications approved by US FDA as of 15-30 May which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

28 Apr 2017
Silymarin does not appear to be significantly better than placebo in reducing disease activity by 30 percent or more in patients with nonalcoholic steatohepatitis (NASH), according to the results of a trial.
08 May 2017
Transabdominal bowel wall ultrasonography shows utility in monitoring disease activity in patients with active Crohn’s disease (CD), according to a study. The imaging technique is ideal for evaluating early transmural changes in disease activity, in response to medical treatment.